| 000 | 01599 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517050335.0 | ||
| 264 | 0 | _c20161014 | |
| 008 | 201610s 0 0 eng d | ||
| 022 | _a1099-081X | ||
| 024 | 7 |
_a10.1002/bdd.1986 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAlqahtani, Saeed | |
| 245 | 0 | 0 |
_aDevelopment of a physiologically based pharmacokinetic/pharmacodynamic model to identify mechanisms contributing to entacapone low bioavailability. _h[electronic resource] |
| 260 |
_bBiopharmaceutics & drug disposition _cDec 2015 |
||
| 300 |
_a587-602 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntiparkinson Agents _xblood |
| 650 | 0 | 4 | _aBiological Availability |
| 650 | 0 | 4 | _aBiotransformation |
| 650 | 0 | 4 | _aCaco-2 Cells |
| 650 | 0 | 4 |
_aCatechol O-Methyltransferase Inhibitors _xblood |
| 650 | 0 | 4 |
_aCatechols _xblood |
| 650 | 0 | 4 | _aComputational Biology |
| 650 | 0 | 4 |
_aEnterocytes _xmetabolism |
| 650 | 0 | 4 | _aExpert Systems |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIntestinal Absorption |
| 650 | 0 | 4 |
_aLiver _xmetabolism |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMetabolic Clearance Rate |
| 650 | 0 | 4 | _aModels, Biological |
| 650 | 0 | 4 |
_aNitriles _xblood |
| 650 | 0 | 4 | _aPhosphorylation |
| 650 | 0 | 4 |
_aProdrugs _xanalysis |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aSolubility |
| 650 | 0 | 4 | _aTissue Distribution |
| 700 | 1 | _aKaddoumi, Amal | |
| 773 | 0 |
_tBiopharmaceutics & drug disposition _gvol. 36 _gno. 9 _gp. 587-602 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/bdd.1986 _zAvailable from publisher's website |
| 999 |
_c25190805 _d25190805 |
||